Nearly all respondents on bmj.com listed Kawasaki disease in the differential diagnosis, even though the duration of illness was only five days. One criterion of Kawasaki disease is fever for 10 days, but intravenous immunoglobulin has been shown to reduce the risk of coronary damage definitely only if administered by day 10.1 Later administration has not been so thoroughly evaluated, and intravenous immunoglobulin may be more effective when given within 5 days than between 5 and 10 days.2 Thus the dilemma when confronted with a febrile child is at what point to acknowledge that Kawasaki disease is likely.
Acute self limiting feverish illnesses are common in young children, and some diagnoses do have specific treatments, particularly streptococcal and other bacterial infections. Streptococcal and staphylococcal sepsis may be linked with Kawasaki disease.3 Treatment with intravenous immunoglobulin is associated with some risks, although they are not well quantified in Kawasaki disease. Thus, there are clinical and practical reasons for not treating every young child with high fever for two or three days with intravenous immunoglobulin. Nevertheless, it is highly desirable to treat before day 10 of Kawasaki disease.
Management
Echocardiography is sensitive in detecting proximal coronary artery aneurysms in Kawasaki disease (figure) and acute distal lesions are rare without proximal ones. Unequivocal coronary lesions are not commonly present before 10 days, although other less specific features may be found, including pericardial effusion and valvar regurgitation. Many recommend echocardiography when Kawasaki disease is suspected, but abnormalities are unlikely to be found before 10 days and their presence would rarely alter management. Thus a decision to treat a child for Kawasaki disease within 10 days usually has to be made without supportive evidence from cardiac examination, electrocardiography, or echocardiography.
Figure 1.
Parasternal short axis echocardiogram in a young child with Kawasaki disease. The left main and anterior descending coronary arteries (LAD) are both tortuous with aneurysmal dilation
Most would advocate the use of intravenous immunoglobulin after day 10 in a systemically unwell child, although the evidence for cardiac rather than symptomatic benefit is lacking. When echocardiography is performed early it needs to be repeated late in the second or in the third week to avoid missing coronary damage.
Aspirin (30 to 100 mg/kg/day) is used until fever settles and then continued at an antiplatelet dose (5 mg/kg/day) until 6-8 weeks after the illness even if no coronary abnormalities are detected. Low dose aspirin is continued longer if coronary abnormalities persist. Parents should be advised about the association between aspirin and Reye's syndrome, and a local protocol for dealing with children taking aspirin who get or have close contact with chickenpox and flu should exist. The role of corticosteroid treatment in Kawasaki disease is unclear but longstanding views that it is deleterious may not be correct.1,4
Competing interests: None declared.
References
- 1.Brogan PA, Bose A, Burgner D, Shingadia D, Tulloh R, Michie C, et al. Kawasaki disease: an evidence based approach to diagnosis, treatment, and proposals for future research. Arch Dis Child 2002;86: 286-90. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Tse SM, Silverman ED, McCrindle BW, Yeung RS. Early treatment with intravenous immunoglobulin in patient with Kawasaki disease. J Pediatr 2002;140: 450-5. [DOI] [PubMed] [Google Scholar]
- 3.Royle JA, Williams K, Elliott E, Sholler G, Nolan T, Allen R, et al. Kawasaki disease in Australia, 1993-95. Arch Dis Child 1998;78: 33-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Sundel RP, Baker A, Fulton DR, Newburger JW. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomised trial. J Pediatr 2003;142: 611-6. [DOI] [PubMed] [Google Scholar]

